Recombinant humanized anti-PEAR1 monoclonal antibody (Shanghai Xunyao Biotechnology)

重组抗PEAR1人源化单克隆抗体（上海循曜生物）

Report date: 2023/12/26 14:55:49

Base Information

Drug NameRecombinant humanized anti-PEAR1 monoclonal antibody (Shanghai Xunyao Biotechnology)
Drug Alias Name重组抗PEAR1人源化单克隆抗体
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-Platelet endothelial aggregation receptor 1
TargetsPlatelet endothelial aggregation receptor 1
Therapy Area/IndicationsIdiopathic Pulmonary Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Xunyao Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Xunyao Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsIdiopathic Pulmonary Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A